drugset / Trial / NCT07256782
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of QLC5508 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Timeline
- Start
- 2025-10-24
- Primary completion
- 2026-10
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | QL2107 | Unknown | 200 mg | Intravenous |
| Subject | QLC5508 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | QLC5508 | Other / unclassified | 2.4 mg/kg | Intravenous |
| Subject | fluorouracil | Small molecule | 800 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |